Paul Miller has joined Artizan Biosciences as chief scientific officer, the same position he held at Synlogic (NASDAQ: [[ticker:SYBX]]). Miller’s experience also includes senior roles at AstraZeneca (NYSE: [[ticker:AZN]]) and Pfizer (NYSE: [[ticker:PFE]]). New Haven, CT-based Artizan Bio, a spinout of Yale University, is developing drugs that target the gut microbiome.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease
A number of startups are targeting the gut microbiome as a way to potentially treat disease, but identifying specific microbes at the root of illness is a challenge. Although software that analyzes troves of biological data helps, the trillions of gut microbes make the research like looking for a needle in a haystack, says James … Continue reading “With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease”
Vertex Pharma Shells Out $420M to Move Into Muscular Dystrophy
Vertex Pharmaceuticals is committing $420 million in a pair of deals that expand the company’s research scope to experimental genetic treatments for two forms of muscular dystrophy. Boston-based Vertex (NASDAQ: [[ticker:VRTX]]) announced late Thursday that it reached an agreement to pay $245 million up front to acquire Exonics, a company using gene editing techniques to … Continue reading “Vertex Pharma Shells Out $420M to Move Into Muscular Dystrophy”
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
Grail CEO Jennifer Cook has stepped down from the cancer diagnostics developer and its board of directors. Menlo Park, CA-based Grail said Thursday that Cook left due to “family health reasons.” Hans Bishop, a Grail director since last August, was appointed Cook’s successor in the chief executive role. He will also remain on Grail’s board. … Continue reading “Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO”
Agios Chief Scientific Officer Scott Biller to Retire at End of Year
Scott Biller, chief scientific officer of Agios Pharmaceuticals (NASDAQ: [[ticker:AGIO]]) since 2010, is retiring at the end of this year. The Cambridge, MA-based company said that Biller will continue as an advisor through the end of 2020. Agios, which develops drugs to treat cancer and rare diseases, is searching for Biller’s successor. Last year, Agios … Continue reading “Agios Chief Scientific Officer Scott Biller to Retire at End of Year”
BlueRock’s Lodie Joins Gamida Cell as Chief Scientific Officer
Gamida Cell (NASDAQ: [[ticker:GMDA]]) has appointed Tracey Lodie to serve as its chief scientific officer. She succeeds Tony Peled, who will move to the newly created chief technology officer position. Lodie comes to Gamida Cell from BlueRock Therapeutics, where she was senior vice president, translational immunology. Gamida Cell, which is based in Israel and maintains … Continue reading “BlueRock’s Lodie Joins Gamida Cell as Chief Scientific Officer”
Immunovant Hires Salzmann Away From Eli Lilly for CEO Post
Veteran Eli Lilly (NYSE: [[ticker:LLY]]) executive Pete Salzmann has been appointed CEO of Immunovant. Salzmann has spent 20 years at Lilly, most recently as global clinical development leader for baricitinib (Olumiant), the rheumatoid arthritis drug that won FDA approval last year. Immunovant, which splits its operations between New York and Basel, Switzerland, is a subsidiary … Continue reading “Immunovant Hires Salzmann Away From Eli Lilly for CEO Post”
LabCorp CEO David King to Retire, Adam Schechter Named Successor
David King, president and CEO of LabCorp (NYSE: [[ticker:LH]]) since 2007, is retiring. The Burlington, NC-based diagnostics and laboratory testing company said that after King retires on Oct. 31, he will become executive director of the company’s board of directors. LabCorp’s current lead independent director, Adam Schechter, will succeed King as president and CEO on … Continue reading “LabCorp CEO David King to Retire, Adam Schechter Named Successor”
Novartis’s Hirawat to Join Bristol-Myers as Chief Medical Officer
Samit Hirawat is joining Bristol-Myers Squibb (NYSE: [[ticker:BMY]]) to become chief medical officer, global drug development. Hirawat was most recently executive vice president and head of oncology development at Novartis (NYSE: [[ticker:NVS]]). He’ll start his new role after Bristol completes its acquisition of Celgene (NASDAQ: [[ticker:CELG]]). In other C-suite moves, Bristol said that Tom Lynch, … Continue reading “Novartis’s Hirawat to Join Bristol-Myers as Chief Medical Officer”
Ex-Vertex Pharma Exec Patricia Hurter to Join Lyndra as CEO
Patricia Hurter is joining Lyndra Therapeutics to become the Watertown, MA, company’s CEO. She will start her new role on Sept. 3. Hurter’s experience includes serving as senior vice president of pharmaceutical and preclinical sciences at Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]). Lyndra’s current CEO, Amy Schulman, will become executive chair of the company’s board. Lyndra is … Continue reading “Ex-Vertex Pharma Exec Patricia Hurter to Join Lyndra as CEO”
Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache
An Eli Lilly migraine drug that was approved last fall now has the regulatory nod to treat a rarer form of headache that tends to occur in clusters. The FDA on Tuesday approved the Lilly (NYSE: [[ticker:LLY]]) drug galcanezumab (Emgality) for episodic cluster headaches, which patients experience as one to four headaches per day, each … Continue reading “Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache”
Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance
Bayer is committing $115 million to Arvinas in a partnership focused on turning the biotech’s technology for getting rid of harmful proteins into new products for both human health and agriculture. According to the deal announced Tuesday, the German life sciences and agtech giant will pay New Haven, CT-based Arvinas (NASDAQ: [[ticker:ARVN]]) more than $60 … Continue reading “Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance”
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval
Bluebird Bio has won regulatory approval for its first gene therapy, a treatment for the rare blood disease beta thalassemia. Cambridge, MA-based Bluebird said Monday that the European Commission’s regulatory nod for its therapy, Zynteglo, is a conditional approval, meaning the decision was made with less data than typically required for new drugs. Such approvals … Continue reading “Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval”
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More
[Corrected 5/31/19, 8:48 am ET. See below.] Pharmaceutical companies that make or market opioids have found themselves in legal hot water, and much of the heat is coming from Oklahoma. This week, a trial began litigating Johnson & Johnson’s responsibility for opioid addiction in the Sooner State. Johnson & Johnson (NYSE: [[ticker:JNJ]]) entered the Norman, … Continue reading “Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More”
Bristol Myers’ Mercier to Join Gilead as Chief Commercial Officer
Johanna Mercier has been appointed chief commercial officer of Gilead Sciences (NASDAQ: [[ticker:GILD]]). Mercier is joining the Foster City, CA, company from Bristol Myers Squibb (NYSE: [[ticker:BMY]]), where she was president and head of the company’s large markets division. Laura Hamill, Gilead’s executive vice president of worldwide commercial operations, is leaving the company. Mercier is … Continue reading “Bristol Myers’ Mercier to Join Gilead as Chief Commercial Officer”
Alnylam Pharma Promotes Kevin Fitzgerald to Chief Scientific Officer
Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) has promoted Kevin Fitzgerald, its head of research, to senior vice president and chief scientific officer. Fitzgerald joined Cambridge, MA-based Alnylam in 2005. In other moves, Alnylam appointed Kelley Boucher senior vice president and chief human resources officer. Boucher was most recently vice president and head of global human resources for … Continue reading “Alnylam Pharma Promotes Kevin Fitzgerald to Chief Scientific Officer”
Vertex Selects Drug Combo, a Potential Therapy for 90% of CF Patients
[Updated, 12:57 p.m. See below.] Vertex Pharmaceuticals is already a leader in cystic fibrosis therapies. The company is placing its bet on an experimental drug that could strengthen its dominant position. Vertex said it will file for regulatory approval of VX-445, an experimental drug that the company estimates could treat up to 90 percent of … Continue reading “Vertex Selects Drug Combo, a Potential Therapy for 90% of CF Patients”
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
Diabetes treatments available today include shots and pills intended to restore the hormone balance that leads to healthy blood sugar levels. Whole Biome aims to accomplish the same thing—but with a capsule that targets the gut microbiome. Whole Biome is preparing to launch its product early next year. To support those plans, the San Francisco-based … Continue reading “With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes”
Atara Bio Appoints Pascal Touchon as Isaac Ciechanover’s Successor
Pascal Touchon has been appointed president and CEO of Atara Biotherapeutics (NASDAQ: [[ticker:ATRA]]). He is also joining the South San Francisco company’s board of directors. He succeeds Isaac Ciechanover, who announced earlier this year that he would step down as president, CEO, and board member. Atara said Ciechanover will serve as a special advisor to … Continue reading “Atara Bio Appoints Pascal Touchon as Isaac Ciechanover’s Successor”
Vertex Exec Sepp-Lorenzino Named Intellia Chief Scientific Officer
Laura Sepp-Lorenzino has joined Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]) as executive vice president and chief scientific officer. She comes to the Cambridge, MA, drug developer from Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]), where she was vice president, head of nucleic acid therapies, research leadership, as well as a member of the company’s external innovation team. Her experience also … Continue reading “Vertex Exec Sepp-Lorenzino Named Intellia Chief Scientific Officer”
The Biotech IPO Queue Grows Longer as Five More Companies File
The biotech IPO train is rolling onward, with five more companies climbing aboard. The companies, ranging from a late-stage firm looking to finance Phase 3 studies to preclinical companies laying the groundwork for their first drug trials with human subjects, submitted their paperwork to the SEC late Friday—just before the start of Memorial Day weekend. Here’s … Continue reading “The Biotech IPO Queue Grows Longer as Five More Companies File”
Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic
After Stoke Therapeutics closed $90 million in financing last fall, CEO Ed Kaye signaled his biotech would seek more cash through an IPO soon. The preclinical-stage biotech is now officially on a path to the public markets. In paperwork filed late Thursday with the SEC, Bedford, MA-based Stoke set a preliminary $86 million target for … Continue reading “Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic”
Nektar Forms New Company Inheris to Take Reins on Pain, CNS Drugs
If Nektar Therapeutics wins FDA approval this summer for an opioid painkiller it designed to be less addictive than other opioids, another company will usher the new product onto the market. San Francisco-based Nektar (NASDAQ: [[ticker:NKTR]]) announced Thursday that it formed Inheris Biopharma to take the reins on pain drug NKTR-181, as well as several … Continue reading “Nektar Forms New Company Inheris to Take Reins on Pain, CNS Drugs”
Ideaya and Bicycle Therapeutics IPOs Raise $110M for Cancer Drug R&D
Ideaya Biosciences and Bicycle Therapeutics priced their IPOs late Wednesday, raising a combined $110 million to continue clinical trials of their respective experimental cancer drugs. South San Francisco-based Ideaya raised $50 million. The company priced its offering of 5 million shares at $10 apiece, well below the targeted price range of $13 to $15 per … Continue reading “Ideaya and Bicycle Therapeutics IPOs Raise $110M for Cancer Drug R&D”
Former Arsanis CEO René Russo Tapped to Lead Akrevia Therapeutics
René Russo has been appointed CEO of Akrevia Therapeutics. She is also joining the Cambridge, MA, company’s board of directors. Russo was most recently CEO of Arsanis (NASDAQ: [[ticker:ASNS]]), a biotech that combined operations with X4 Pharmaceuticals in a reverse merger earlier this year. Launched last year with $30 million in financing, Akrevia is developing … Continue reading “Former Arsanis CEO René Russo Tapped to Lead Akrevia Therapeutics”
Celsius Therapeutics Adds Greg Ryslik and Michael Boretti to C-Suite
Greg Ryslik has been appointed chief data officer of Celsius Therapeutics. He joins the Cambridge, MA-based company from Mindstrong Health, where he was vice president of data science. His experience also includes posts at electric carmakers Faraday Future and Tesla (NASDAQ: [[ticker:TSLA]]). In other moves, Celsius appointed Michael Boretti, formerly vice president of business development … Continue reading “Celsius Therapeutics Adds Greg Ryslik and Michael Boretti to C-Suite”
Agrilyst Rebrands as Artemis, Lands $8M for Indoor Farming Software
Agrilyst, an agtech startup that has commercialized software that helps manage indoor farms and greenhouses, is unveiling a new name and additional capital. The company is now called Artemis and it has raised an $8 million Series A round of funding. Astanor Ventures and Talis Capital co-led the investment announced Wednesday. Other investors include New … Continue reading “Agrilyst Rebrands as Artemis, Lands $8M for Indoor Farming Software”
With $120M, AlloVir Faces Big Test of Cell Therapy to Fight Infection
In healthy people, viruses are kept in check by the immune system. But for immunocompromised patients, such as those undergoing transplant procedures, a viral infection is potentially deadly. AlloVir is developing a cell therapy intended to control infections while a patient’s immune system recovers. Houston-based AlloVir is preparing its lead candidate for late-stage testing and … Continue reading “With $120M, AlloVir Faces Big Test of Cell Therapy to Fight Infection”
Merck Preempts Peloton Therapeutics IPO With $1B Acquisition Deal
Merck has reached a deal to acquire Peloton Therapeutics, and its Phase 3-ready kidney cancer drug, for $1.05 billion. Under the agreement announced Tuesday, Merck (NYSE: [[ticker:MRK]]) will pay the sum in cash up front. If Peloton’s drug candidates reach the market and hit sales targets, shareholders of privately held Pelton could gain up to … Continue reading “Merck Preempts Peloton Therapeutics IPO With $1B Acquisition Deal”
Voyager’s CSO Dinah Sah to Retire, Omar Khwaja Expands Role
Dinah Sah is retiring from her position as chief scientific officer of Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]). In her place, the Cambridge, MA-based gene therapy developer said that Chief Medical Officer Omar Khwaja will take on an expanded role as chief medical officer and head of research and development. The changes will happen June 28, but … Continue reading “Voyager’s CSO Dinah Sah to Retire, Omar Khwaja Expands Role”
Animal Bio Picks Tufts’ Rentko for Chief Veterinary Medical Officer
Ginny Rentko has been appointed chief veterinary medical officer of Animal Biosciences, a subsidiary of Boston-based Life Biosciences. Rentko comes to Animal Bio from Tufts University, where she was medical director of the Cummings School of Veterinary Medicine. Animal Bio is developing therapeutics and supplements intended to help pets live longer.
Eiger Bio’s Apelian Gives Notice, Takes CEO Job at Private Biotech
David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: [[ticker:EIGR]]) for the past 17 months, is stepping down. The Palo Alto, CA, drug developer said Friday that Apelian accepted an offer to become CEO of an unnamed private biotech company. Apelian, whose last day will be June 14, will remain on … Continue reading “Eiger Bio’s Apelian Gives Notice, Takes CEO Job at Private Biotech”
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But such tools only work when companies play fair. A lawsuit is now claiming that … Continue reading “Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More”
Pulmatrix CEO Robert Clarke Steps Down, Ted Raad Appointed Successor
Robert Clarke, the chief executive who led Pulmatrix to the public markets via a reverse merger in 2015, has stepped down from the company and its board of directors. The Lexington, MA-based company gave no reason for the departure of Clarke, who was promoted from chief scientific officer to CEO in 2012. But Pulmatrix (NASDAQ: … Continue reading “Pulmatrix CEO Robert Clarke Steps Down, Ted Raad Appointed Successor”
Ginkgo Eyes Antibiotics With Deal for Warp Drive’s Gene “Mining” Tech
Microbes designed by Ginkgo Bioworks are used in consumer products such as fragrances and beverages, and they’re undergoing research for applications in agriculture and medicine. The synthetic biology company has been pushing to expand its technology to more uses, and its latest deal moves the firm further into pharmaceutical research. Boston-based Ginkgo said Wednesday that … Continue reading “Ginkgo Eyes Antibiotics With Deal for Warp Drive’s Gene “Mining” Tech”
Glympse Bio Names NIBR’s Winckler to Chief Scientific Officer Post
Wendy Winckler has been appointed chief scientific officer of Glympse Bio. She joins Cambridge, MA-based Glympse from the Novartis Institutes for Biomedical Research (NIBR), where she was executive director of next generation diagnostics. Winckler’s experience also includes posts at the Broad Institute of MIT and Harvard, as well as the Dana Farber Cancer Institute. Glympse, … Continue reading “Glympse Bio Names NIBR’s Winckler to Chief Scientific Officer Post”
Bavarian Nordic’s Heery Joins Precision Bio as Chief Medical Officer
Christopher Heery has joined Precision BioSciences (NASDAQ: [[ticker:DTIL]]) as chief medical officer, the same position he held at his former company, Bavarian Nordic. Heery’s experience also includes time at the National Cancer Institute where he was head of the clinical trials group of the laboratory of tumor immunology and biology. Durham, NC-based Precision Bio completed … Continue reading “Bavarian Nordic’s Heery Joins Precision Bio as Chief Medical Officer”
Klickstein Leaves NIBR for resTORbio Chief Scientific Officer Role
Lloyd Klickstein has joined resTORbio (NASDAQ: [[ticker:TORC]]) as chief scientific officer. Klickstein comes to Boston-based resTORbio from the Novartis Institutes for Biomedical Research (NIBR), where was global head of translational medicine for the new indication discovery unit and the exploratory disease area. Last year, resTORbio reported positive data for lead drug RTB101, which was developed … Continue reading “Klickstein Leaves NIBR for resTORbio Chief Scientific Officer Role”
Advaxis Chief Scientific Officer Robert Petit to Step Down in June
Robert Petit, chief scientific officer of Advaxis (NASDAQ: [[ticker:ADXS]]) for the past six years, is stepping down. In a securities filing, the Princeton, NJ, drug developer said Petit’s last day will be June 3 and his departure is not related to any disagreement about the company’s operations, policies, or practices. Advaxis added that Petit will … Continue reading “Advaxis Chief Scientific Officer Robert Petit to Step Down in June”
ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups
When a biotech startup is ready to test an experimental therapy it faces a pricey choice: Should it make its drug in-house, or hire a contract manufacturer? The decision is particularly expensive for companies developing complex gene and cell therapies, which need to make large batches of engineered viruses to test their work. A new … Continue reading “ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups”
Two Days, Five Biotech IPOs, and $359M Raised for Clinical Trials
It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital, 47 IPOs have … Continue reading “Two Days, Five Biotech IPOs, and $359M Raised for Clinical Trials”
Goldfinch Bio Lands $55M From Gilead in Kidney Drug R&D Pact
Goldfinch Bio set out to build a database of patients with kidney diseases, which it could study to understand the biology and genetics of kidney disorders in order to develop better drugs. The biotech startup is making headway on its research and its approach now has some outside validation. Gilead Sciences is partnering with Goldfinch … Continue reading “Goldfinch Bio Lands $55M From Gilead in Kidney Drug R&D Pact”
Former Juno Exec Stern Joins FogPharma as Chief Scientific Officer
FogPharma has appointed Howard Stern to serve as its chief scientific officer. Before joining the Boston company, Stern was vice president of translational sciences at Juno Therapeutics, which was acquired by Celgene (NASDAQ: [[ticker:CELG]]) in 2015. Stern’s experience also includes posts at Infinity Pharmaceuticals and Genentech. In other moves, FogPharma named Peter Fekkes vice president of … Continue reading “Former Juno Exec Stern Joins FogPharma as Chief Scientific Officer”
Kyn Therapeutics Promotes Jeffrey Ecsedy, Jason Sager to C-Suite
Kyn Therapeutics has two new executives on its management team. Jeffrey Ecsedy, the Boston company’s senior vice president, R&D, was promoted to chief scientific officer. Also, Jason Sager is now chief medical officer after holding that post on an interim basis for the past two years. Kyn emerged in 2017 with $49 million in funding to … Continue reading “Kyn Therapeutics Promotes Jeffrey Ecsedy, Jason Sager to C-Suite”
Bellicum Pharma’s Grossman Joins Arcus Bio as Chief Medical Officer
William Grossman has joined Arcus Biosciences (NYSE: [[ticker:RCUS]]) as chief medical officer, the same position he held at his former company, Bellicum Pharmaceuticals (NASDAQ: [[ticker:BLCM]]). Grossman’s experience also includes positions at Genentech, AbbVie (NYSE: [[ticker:ABBV]]), and Biothera. Hayward, CA-based Arcus, which raised $120 million in its IPO last year, has several cancer drugs in early-stage … Continue reading “Bellicum Pharma’s Grossman Joins Arcus Bio as Chief Medical Officer”
Athira Pharma Appoints Hans Moebius Chief Medical Officer
Hans Moebius has joined Athira Pharma as chief medical officer. Moebius’s experience includes positions at Ciba-Geigy, Novartis (NYSE: [[ticker:NVS]]), Merz Pharma, TauRx, and Allergan (NYSE: [[ticker:AGN]]). Seattle-based Athira, which recently changed its name from M3 Biotechnology, is currently testing lead drug candidate NDX-1017 in a Phase 1 study in patients with Alzheimer’s disease, dementia, or … Continue reading “Athira Pharma Appoints Hans Moebius Chief Medical Officer”
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
The first new class of migraine drugs in decades won FDA approval last year. But the companies who commercialized these new therapies and their potential competitors are already planning new, more convenient versions, taken as pills instead of injectoins just below the skin, and they will present key data in the next few days at … Continue reading “At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments”
Nohla’s Christianson Joins Rainier Therapeutics as Chief Technical Officer
Gary Christianson has been appointed chief technical officer of San Leandro, CA-based Rainier Therapeutics. Christianson was most recently chief operating officer at Nohla Therapeutics in Seattle. His experience also includes posts at Cascadian Therapeutics and GlaxoSmithKline (NYSE: [[ticker:GSK]]). Rainier, formerly known as BioClin Therapeutics, has advanced its lead drug candidate vofatamab to Phase 2 testing … Continue reading “Nohla’s Christianson Joins Rainier Therapeutics as Chief Technical Officer”
SeaGen’s Josephson Jumps to Zymeworks to Lead Clinical Research
Neil Josephson is joining Zymeworks (NYSE: [[ticker:ZYME]]) to become vice president of clinical research. Josephson comes to the Vancouver, BC-based drug developer from Seattle Genetics (NASDAQ: [[ticker:SGEN]]), where he was vice president of clinical development. In other moves, Zymeworks appointed Mark Hollywood to serve as senior vice president, technical and manufacturing operations, and Bruce Hart … Continue reading “SeaGen’s Josephson Jumps to Zymeworks to Lead Clinical Research”
Beyond Meat’s IPO Bags $241M to Make Plant-Based Burgers Mainstream
A Beyond Meat burger is coming to a location near you—and soon. The food technology company’s upsized IPO has raised $241 million to finance plans to bring its plant-based “meat” to more grocery stores and restaurants across the country. Beyond Meat priced its IPO Wednesday evening at $25 per share, which was the high end … Continue reading “Beyond Meat’s IPO Bags $241M to Make Plant-Based Burgers Mainstream”